Furoscix® (furosemide) – Expanded indication

- On August 12, 2024, scPharmaceuticals announced the FDA approval of Furoscix (furosemide), for the treatment of congestion due to fluid overload in adult patients with chronic heart failure.
    - Furoscix was previously approved for this indication in patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
    - The updated indication now includes patients with NYHA Class IV chronic heart failure.
- Patients with NYHA Class IV chronic heart failure are the most symptomatic patients and those with the greatest limitation on physical activity. This population represents approximately 10% of all heart failure cases.
- Furoscix is administered as a subcutaneous single-use, on-body infusor with prefilled cartridge that is pre-programmed to deliver 30 mg of furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours.
    - Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical.
    - Furoscix is intended for use in a setting where the patient can limit their activity for the duration of administration.